Trospium chloride in the treatment of idiopathic and neurogenic detrusor overactivity


Cite item

Full Text

Abstract

The aim of the study was to investigate safety and efficacy of spasmex (trospium chloride) in patients with idiopathic and neurogenic detrusor overactivity. The study included 66 patients with idiopathic and neurogenic detrusor overactivity. The diagnostic scheme consisted of voiding dairy for 72 hours, laboratory tests, ultrasound investigation with measurement of residual urine volume, urodynamic investigation and neurologic examination. The patients were divided into 4 groups- 15 patients with idiopathic detrusor overactivity (DOA), 16 with neurogenic DOA, 23 with combination of DOA with benign prostatic hyperplasia, 12 with overactive bladder without DOA. Initial trospium chloride dose of 15 mg/day (5 mg 3 times a day) followed by dose titration to obtain clinical efficacy was used under residual urine volume control every week. The maximal dose was 45 mg. After 12 weeks reduction of micturation frequency was registered in all the groups Administration of small dose trospium chloride (15 mg) resulted in subjective improvement in 63 (94.5%) patients. Only 3 patients persisted with the symptoms in whom the dose was raised to 30 mg and then to 45 mg/day. Thus, spasmex demonstrated high efficacy in patients with bladder overactivity. High efficacy and safety with low cost make spasmex a drug of choice in the majority of patients with overactive bladder symptoms.

References

  1. Milsom I. The prevalence of overactive bladder. In: 14-th Congress of the European association of gynecology and obstetrics. Grenada; 1999.
  2. Пушкарь Д. Ю., Щавелева О. Б. Распространенность императивных нарушений мочеиспускания среди женщин. В кн.: Материалы Пленума правления Росссийского о-ва урологов. 2001. 150-151.
  3. Alloussi S., Laval K.-U., Eckert R. et al. Trospium chloride in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. J. Clin. Res. 1998; 1: 439-451.
  4. Boone Т. В., Payne С. К., Gormlrey. Diagnosis and treatment of urge incontinence. AUA News 2000; 5 (6): 9-10.
  5. Igawa Y. Disscushion: functional roel of Ml, M2, and M3 muscarinic receptors in overactive bladder. Urology 2000; 55 (suppl. 5A): 47-49.
  6. Staskin D. R., Harnett M. D. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr. Urol. Rep. 2004; 5: 423-426.
  7. Beckmarm-Knopp S., Rietbrock S., Weyhenmeyer R. et al. Inhibitory effects of trospium chloride on cytochrome P 450 enzyms in human liver microsomes. Pharmacol, and Toxicol. 1999; 85: 299-304.
  8. Walter P., Grosse I., Bihr A. M. et al. Bio availability of trospium chloride after intravesical instillation in patiens with neurogenic lower urinary tract dysfinction; a pilot study. Neurourol. and Urodyn. 1999; 18: 447-453.
  9. Abrams P., Caplan S., Millard R. Tolterodine treatment is safe in men with bladder outlet obstruction and symptomatic detrusor overactivity. In: Proceedings of the International continence society. 32nd Annual meeting. Seoul; 2001. 107.
  10. Athanasopoulos A., Gyfopoulos K., Giannitsas et al. Combination treatment with an (-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J. Urol. (Baltimore) 2003; 169: 2253-2256.
  11. Schmidt Т., Wickner R., Keiffer A. et al. Effekt of the quternary ammonium compound trospium chloride on 24 hour jejunal motility in healthy subjects. Gut 1994; 35: 27-33.
  12. Cardozo L., Chappie С. R., Tooz-Hobson P. et al. Efficacy of trospium chloride in patients with detrusor instability: a placebocontrolled, randomized, double-blind, multicentre clinical trial. Br. J. Urol. Int. 2000; 85: 659-664.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2005 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies